Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study

Catheterization and Cardiovascular Interventions

Volumn 86, Issue 7, 2015, Pages 1141-1150

  Rusinaru, Dan ^a   Vrolix, Mathias ^b   Verheye, Stefan ^c   Chowdhary, Saqib ^d   Schoors, Danny ^e   Di Mario, Carlo ^f   Desmet, Walter ^g   Donohoe, Dennis J ^h   Ormiston, John A ⁱ   Knape, Charlene ^h   Bezerra, Hiram ^j   Lansky, Alexandra ^k   Wijns, William ^a  

^a CARDIOVASCULAR CENTER   (Belgium)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c Hospital Network Antwerp   (Belgium)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h Micell Technologies Inc   (United States)

ⁱ AUCKLAND CITY HOSPITAL   (New Zealand)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

coronary angiography; coronary stenting; endothelial function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; POLYMER; RAPAMYCIN; ZOTAROLIMUS;

ABSORBABLE POLYMER SIROLIMUS-ELUTING STENT; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENTING; DIABETES MELLITUS; FEMALE; HEART ATRIUM PACING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRESERVED CORONARY VASOMOTION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SIROLIMUS ELUTING CORONARY STENT; TREATMENT RESPONSE; VASCULAR EQUIPMENT; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DEVICES; DRUG ELUTING STENT; EPIDEMIOLOGY; EUROPE; HEART PACING; MIDDLE AGED; NEW ZEALAND; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RADIOGRAPHY; TIME FACTOR; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; CARDIAC PACING, ARTIFICIAL; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; EUROPE; FEMALE; HISTORICALLY CONTROLLED STUDY; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATION;

EID: 84947615371     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25610     Document Type: Article

References (34)

1. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB,. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R,; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
3. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD,. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181.
4. Camenzind E, Steg PG, Wijns W,. Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern. Circulation 2007; 115: 1440-1455.
5. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M,. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: Evaluated by optical coherence tomography. Eur Heart J 2007; 28: 961-967.
6. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S,. Incomplete neointimal coverage of sirolimus-eluting stents: Angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-2111.
7. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R,. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
8. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
9. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction J Am Coll Cardiol 2005; 46: 231-236.
10. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW,. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006; 27: 166-170.
11. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, Ntalianis A, Muller O, Barbato E, Beleslin B, Sagic D, De Bruyne B, Bartunek J, Wijns W,. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: Evidence for device-specific responses. Circ Cardiovasc Interv 2008; 1: 193-200.
12. Minami Y, Kaneda H, Inoue M, Ikutomi M, Morita T, Nakajima T,. Endothelial dysfunction following drug-eluting stent implantation: A systematic review of the literature. Int J Cardiol 2013; 165: 222-228.
13. Carlyle WC, McClain JB, Tzafriri AR, Bailey L, Zani BG, Markham PM, Stanley JR, Edelman ER,. Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. J Control Release 2012; 162: 561-567.
14. Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W,. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: Imaging and clinical results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries). JACC Cardiovasc Interv 2013; 6: 1026-1034.
15. Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Donohoe D, Knape C, Attizzani GF, Lansky AJ, Ormiston J,. Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: Results of the DESSOLVE II trial. Eurointervention 2015; 10: 1383-1390.
16. Garg S, Serruys PW,. Coronary stents: Current status. J Am Coll Cardiol 2010; 56 (10 Suppl): S1-S42.
17. Maier W, Windecker S, Küng A, Lütolf R, Eberli FR, Meier B, Hess OM,. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circulation 2002; 105: 2373-2377.
18. Kim JW, Suh SY, Choi CU, Na JO, Kim EJ, Rha SW, Park CG, Seo HS, Oh DJ,. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. JACC Cardiovasc Interv 2008; 1: 65-71.
19. Obata JE, Kitta Y, Takano H, Kodama Y, Nakamura T, Mende A, Kawabata K, Saitoh Y, Fujioka D, Kobayashi T, Yano T, Kugiyama K,. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 2007; 50: 1305-1309.
20. Pendyala LK, Li J, Shinke T, Geva S, Yin X, Chen JP, King SB, 3rd, Robinson KA, Chronos NA, Hou D,. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. JACC Cardiovasc Interv 2009; 2: 253-262.
21. Shiroto T, Yasuda S, Tsuburaya R, Ito Y, Takahashi J, Ito K, Ishibashi-Ueda H, Shimokawa H,. Role of Rho-kinase in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in pigs in vivo. J Am Coll Cardiol 2009; 54: 2321-2329.
22. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ,. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004; 109: 2168-2171.
23. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet EA, Verdouw PD, Serruys PW, van Beusekom HM,. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83: 338-345.
24. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, Nedeljkovic M, Orlic D, Milosavljevic B, Topic D, Karanovic N, Wijns W,; NOBORI CORE Investigators. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008; 51: 2123-2129.
25. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R,. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342.
26. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D,. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
27. Curcio A, Torella D, Cuda G, Coppola C, Faniello MC, Achille F, Russo VG, Chiariello M, Indolfi C,. Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. Am J Physiol Heart Circ Physiol 2004; 286: H902-H908.
28. Busch R, Strohbach A, Rethfeldt S, Walz S, Busch M, Petersen S, Felix S, Sternberg K,. New stent surface materials: The impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets. Acta Biomater 2014; 10: 688-700.
29. Hezi-Yamit A, Sullivan C, Wong J, David L, Chen M, Cheng P, Shumaker D, Wilcox J, Udipi K,. Novel high-throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): Application for evaluating polymer coatings for cardiovascular drug-eluting stents. Comb Chem High Throughput Screen 2009; 12: 664-676.
30. Kim JW, Seo HS, Park JH, Na JO, Choi CU, Lim HE, Kim EJ, Rha SW, Park CG, Oh DJ,. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: Differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol 2009; 53: 1653-1659.
31. Nabel EG, Selwyn AP, Ganz P,. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 1990; 81; 850-859.
32. Shabeeh H, Melikian N, Dworakowski R, Casadei B, Chowienczyk P, Shah AM,. Differential role of endothelial versus neuronal nitric oxide synthase in the regulation of coronary blood flow during pacing-induced increases in cardiac workload. Am J Physiol Heart Circ Physiol 2013; 304: H1277-H1282.
33. Lerman A, Eeckhout E,. Coronary endothelial dysfunction following sirolimus-eluting stent placement: Should we worry about it? Eur Heart J 2006; 27: 125-126.
34. Obata J, Nakamura T, Kitta Y, Kodama Y, Sano K, Kawabata K, Saitoh Y, Fujioka D, Kobayashi T, Yano T, Watanabe Y, Watanabe K, Kugiyama K,. Treatment of acute myocardial infarction with sirolimus-eluting stents results in chronic endothelial dysfunction in the infarct-related coronary artery. Circ Cardiovasc Intervent 2009; 2: 384-391.